L-dopa remains the most common treatment for Parkinson's disease. However, there is considerable interest in D3/D2 receptor agonists such as the novel agent S32504, since they exert antiparkinsonian properties in the absence of dyskinesia. An important question concerns the roles of D2 vs. D3 recept
β¦ LIBER β¦
Neuroprotective effects mediated by dopamine receptor agonists against malonate-induced lesion in the rat striatum
β Scribed by R. Fancellu; M.-T. Armentero; G. Nappi; F. Blandini
- Publisher
- Springer Milan
- Year
- 2003
- Tongue
- English
- Weight
- 69 KB
- Volume
- 24
- Category
- Article
- ISSN
- 1590-1874
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Antiparkinsonian effects of the novel D3
β
Michael P. Hill; Paula Ravenscroft; Steven G. McGuire; Jonathan M. Brotchie; Ala
π
Article
π
2006
π
John Wiley and Sons
π
English
β 95 KB
L-DOPA inhibits depolarization-induced [
β
I. Silva; H. Cortes; E. EscartΓn; C. Rangel; L. FlorΓ‘n; D. Erlij; J. Aceves; B.
π
Article
π
2006
π
Springer
π
English
β 224 KB
Effects of an N-methyl-d-aspartate recep
β
Hideaki Kabuto; Isao Yokoi; Kiminao Mizukawa; Akitane Mori
π
Article
π
1989
π
Springer
π
English
β 830 KB
Neuroprotective effect of guanosine agai
β
Simone Molz; Tharine Dal-Cim; Josiane Budni; M.D. MartΓn-de-Saavedra; Javier Ege
π
Article
π
2011
π
John Wiley and Sons
π
English
β 419 KB
π 2 views
## Abstract Excitotoxicity and cell death induced by glutamate are involved in many neurodegenerative disorders. We have previously demonstrated that excitotoxicity induced by millimolar concentrations of glutamate in hippocampal slices involves apoptotic features and glutamateβinduced glutamate re